Open AccessHigher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease
Author(s) -
Giovanni Alejandro SalgadoÁlvarez,
Samanta Mayanin Pinto Gálvez,
Uriel Garcia Mora,
Ana Delfina Cano Contreras,
Cristina Durán Rosas,
Bryan Adrian PriegoParra,
Arturo Triana Romero,
Mercedes Amieva Balmori,
Federico Röesch Dietlen,
Sophia Eugenia Martinez Vazquez,
Ines Osvely Mendez Guerrero,
Luis Alberto Chi-Cervera,
Raúl Bernal Reyes,
Leonardo Alberto Martinez Roriguez,
Maria Eugenia Icaza Chavez,
José María Remes Troche
Publication year - 2022
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v14.i8.1633
Subject(s) - medicine , transient elastography , framingham risk score , fatty liver , nonalcoholic fatty liver disease , diabetes mellitus , fibrosis , body mass index , hepatic fibrosis , gastroenterology , odds ratio , disease , liver fibrosis , endocrinology
The definition of metabolic-dysfunction-associated fatty liver disease (MAFLD) allows identification of metabolically complicated patients. Fibrosis risk scores are related to cardiovascular risk (CVR) scores and could be useful for the identification of patients at risk of systemic complications.